PHARMACEUTICAL CARRIERS CONTAINING miRNAs FOR USE IN THE TREATMENT OF RENAL CANCER
AssigneeUnicyte Ev AG
InventorsGiovanni CAMUSSI, Benedetta BUSSOLATI, Tatiana LOPATINA
Life of this patent
Estimating the term…
Abstract
A method for treating renal cancer by administering a pharmaceutically acceptable carrier comprising a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof is provided. In an embodiment, the pharmaceutically acceptable carrier is an extracellular vesicle (EV) derived from an adult stem cell selected from the group consisting of a mesenchymal stem cell (MSC), a non-oval human liver progenitor cell (HLSC) and an adipose stem cell (ASC).
Claims19
A method for treating renal cancer, the method comprising administering to a person in need thereof, a pharmaceutically acceptable carrier comprising a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof.
An engineered extracellular vesicle (EV) containing a significantly higher amount of a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof than a naturally-occurring extracellular vesicle (EV), obtainable by loading a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof into an isolated extracellular vesicle ex vivo.
A method of manufacturing an engineered extracellular vesicle (EV), the method comprising loading a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof into the extracellular vesicle by a transfection method selected from the group consisting of electroporation, lipofection, microinjection, transfection by viral and nonviral vectors, magnet assisted transfection, co-incubation and sonoporation.
A method of manufacturing an engineered extracellular vesicle (EV), the method comprising isolating and purifying the extracellular vesicle from a conditioned medium of a cell transfected with a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof by a transfection method selected from the group consisting of electroporation, lipofection, microinjection, transfection by viral and nonviral vectors, magnet assisted transfection, co-incubation and sonoporation.
A method for treating renal cancer, the method comprising administering a composition comprising a mixture of extracellular vesicles (EVs) isolated from the conditioned medium of a stem cell.
Dependencies are inferred from the claim text.